New data from the UK Health Security Agency (UKHSA) indicates significant progress in combating meningitis caused by meningococcal...
After its market withdrawal in 2022, GSK’s multiple myeloma drug Blenrep (belantamab mafodotin) is poised to re-enter the treat...